Trivalent inactivated influenza virus vaccine given to two-month-old children: an off-season pilot study

The Pediatric Infectious Disease Journal
Emmanuel B WalterGRC27 Study Team

Abstract

Although children less than 6 months of age have the highest risk for hospitalization related to influenza infection, influenza vaccine is not approved for these children. In an open-label, off-season study, healthy 6 to 12 week and 6-month-old children received 2 doses of the 2004 to 2005 trivalent inactivated influenza vaccine (TIV) administered 1 month apart along with other routine pediatric vaccines. Safety was assessed by parental diaries (n = 393). Immunogenicity analyses (n = 293) were performed on sera obtained before vaccination and 1 month after the second dose of TIV. Outcomes included the frequencies of subjects with injection site and systemic reactions and seroprotection rates to TIV antigens. Injection site reactions and fevers were generally mild and resolved within 3 days. Postvaccination seroprotection rates (titer > or = 1:40) in the 6- to 12-week-old and 6-month-old groups were 46% and 69% to A/New Caledonia (H1N1), 59% and 79% to A/Wyoming (H3N2), and 5% and 22% to B/Jiangsu (P < 0.001, all comparisons). For seronegative 6- to 12-week-olds whose mothers had not received TIV during pregnancy, postvaccination seroprotective titers to A/New Caledonia (H1N1) were achieved in 70% (38/54) and to A/Wyoming (H3N2)...Continue Reading

References

Oct 1, 1995·Archives of Pediatrics & Adolescent Medicine·D A ClementsE Walter
Aug 26, 1998·JAMA : the Journal of the American Medical Association·H A GansY Maldonado
Jan 29, 2000·The New England Journal of Medicine·K M NeuzilM R Griffin
Jan 29, 2000·The New England Journal of Medicine·H S IzurietaK Fukuda
Dec 1, 2000·The Pediatric Infectious Disease Journal·R DaganS Ashkenazi
Jan 17, 2002·The New England Journal of Medicine·UNKNOWN The American Lung Association Asthma Clinical Research Centers
Jan 9, 2003·JAMA : the Journal of the American Medical Association·William W ThompsonKeiji Fukuda
Sep 25, 2003·JAMA : the Journal of the American Medical Association·Alejandro HobermanJill D Kerr
Mar 6, 2004·The Journal of Pediatrics·G William LetsonHarold S Margolis
Sep 16, 2004·JAMA : the Journal of the American Medical Association·William W ThompsonKeiji Fukuda
Apr 5, 2005·Pediatrics·Janet A EnglundKathleen M Neuzil
Dec 16, 2005·The New England Journal of Medicine·Niranjan BhatUNKNOWN Influenza Special Investigations Team
Jul 11, 2006·The New England Journal of Medicine·Katherine A PoehlingUNKNOWN New Vaccine Surveillance Network
Oct 4, 2006·Pediatrics·Anne Merewood
May 1, 2008·The Journal of Infectious Diseases·Natasha B HalasaKathryn M Edwards

❮ Previous
Next ❯

Citations

Jun 7, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H SilvennoinenT Heikkinen
Feb 8, 2011·The Pediatric Infectious Disease Journal·Heli SilvennoinenTerho Heikkinen
Jan 29, 2011·The Pediatric Infectious Disease Journal·Carl T D'AngioUNKNOWN Premature Infant Vaccine Collaborative
Nov 30, 2010·Expert Opinion on Biological Therapy·Gian Vincenzo Zuccotti, Valentina Fabiano
Aug 14, 2010·Pediatric Annals·Romina Libster, Kathryn M Edwards
Jun 26, 2015·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·J Li-Kim-MoyR Booy
Jun 20, 2015·Frontiers in Immunology·Alexander W Kay, Catherine A Blish
Jun 4, 2014·Pediatrics in Review·Thomas G Fox, John C Christenson
May 14, 2016·Expert Review of Vaccines·Paul LoubetOdile Launay
May 17, 2017·Paediatric Drugs·Kirsten P Perrett, Terry M Nolan
Dec 17, 2015·Pediatrics International : Official Journal of the Japan Pediatric Society·Tetsu SugimuraRumiko Hirata
Jun 23, 2019·Expert Review of Vaccines·Justin R Ortiz, Kathleen M Neuzil
Jan 3, 2021·NeoReviews·Bahaa Abu-Raya, Kirsten Maertens
Jun 1, 2016·Pediatrics·Julie H ShakibCarrie L Byington
Oct 20, 2010·Pediatrics·Elizabeth P Schlaudecker, Mark C Steinhoff

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.